Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Ractigen’s RAG-01 Shows Early Complete Response in Phase 1 NMIBC Study
Details : RAG-01 stands as a pioneering saRNA candidate from Ractigen Therapeutics, engineered to target and activate the tumor suppressor gene p21, intended for non-muscle-invasive bladder cancer.
Product Name : RAG-01
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 24, 2025
Ractigen Therapeutics Announces First Patient Dosed in Phase I Trial for RAG-17
Details : RAG-17 is a small interfering RNA (siRNA) targeting the Superoxide Dismutase 1 (SOD1) gene in the treatment of amyotrophic lateral sclerosis (ALS) associated with SOD1 mutations (ALS-SOD1).
Product Name : RAG-17
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 24, 2024
Lead Product(s) : RAG-21
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ractigen Gains FDA Orphan Designation for RAG-21 in ALS Therapy Development
Details : RAG-21, its novel siRNA therapy targeting the FUS gene by reducing its level, for the treatment of FUS-amyotrophic lateral sclerosis
Product Name : RAG-21
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : RAG-21
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ractigen Announces Positive Data For RAG-17 in ALS-SOD1 Treatment
Details : RAG-17 is a small interfering RNA (siRNA) targeting the Superoxide Dismutase 1 (SOD1) gene in the treatment of amyotrophic lateral sclerosis (ALS) associated with SOD1 mutations (ALS-SOD1).
Product Name : RAG-17
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : RAG-18
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ractigen Receives FDA Orphan Drug Designation for RAG-18 in DMD and BMD
Details : RAG-18 is a first of its kind saRNA candidate designed to specifically target and activate UTRN gene expression. It is being evaluated for duchenne muscular dystrophy & becker muscular dystrophy.
Product Name : RAG-18
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : RAG-18
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RAG-18
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ractigen Receives FDA Pediatric Disease Designation for RAG-18 in Duchenne Dystrophy
Details : RAG-18 is a first of its kind saRNA candidate designed to specifically target and activate UTRN gene expression. It is being evaluated for duchenne muscular dystrophy & becker muscular dystrophy.
Product Name : RAG-18
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 25, 2024
Lead Product(s) : RAG-18
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ractigen Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy
Details : RAG-01 stands as a pioneering saRNA candidate from Ractigen Therapeutics, engineered to target and activate the tumor suppressor gene p21, intended for non-muscle-invasive bladder cancer.
Product Name : RAG-01
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 21, 2024
Ractigen Therapeutics Receives IND Approval for Phase 1 Trials of RAG-17 in ALS
Details : RAG-17 is a therapeutic siRNA specifically designed to suppress the SOD1 gene in Amyotrophic Lateral Sclerosis patients carrying the Superoxide Dismutase 1 (SOD1) mutation.
Product Name : RAG-17
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 15, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : University Medical Center Utrecht
Deal Size : Undisclosed
Deal Type : Partnership
Ractigen Partners with University Medical Center Utrecht to Advance saRNA in Disorders
Details : This strategic alliance unites their respective strengths to advance the development of saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 29, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : University Medical Center Utrecht
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : RAG-01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01
Details : RAG-01 stands as a pioneering saRNA candidate from Ractigen Therapeutics, engineered to target and activate the tumor suppressor gene p21, intended for non-muscle-invasive bladder cancer.
Product Name : RAG-01
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : RAG-01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
